Management of Postoperative Non-ST-Elevation Myocardial Infarction (NSTEMI)

Immediate Medical Management

The European Society of Cardiology recommends dual antiplatelet therapy with aspirin and clopidogrel for initial medical treatment in acute coronary syndromes without persistent ST-segment elevation 1, 2
Aspirin 75-325 mg should be given immediately if not already administered, and clopidogrel 300-600 mg loading dose followed by 75 mg daily is recommended for patients with NSTE-ACS selected for an invasive approach 1, 2
The postoperative bleeding risk does not contraindicate dual antiplatelet therapy in this setting, as the mortality risk from untreated NSTEMI substantially outweighs bleeding concerns 1, 2

Low-molecular-weight heparin (LMWH) is recommended over unfractionated heparin for acute treatment of NSTE-ACS, and the guidelines recommend LMWH or unfractionated heparin as part of initial medical treatment for NSTE-ACS 1, 2
Continue prophylactic enoxaparin and add unfractionated heparin for more precise control given recent surgery 1, 2

Beta-blockers are recommended as a cornerstone of initial medical management in NSTE-ACS to reduce myocardial oxygen demand by decreasing heart rate and blood pressure, with a target heart rate of 50-60 beats per minute 3
Metoprolol should be titrated upward as tolerated while monitoring for hypotension or bradycardia 3

Continue high-intensity statin therapy, targeting LDL-C <55 mg/dL, and initiate an ACE inhibitor within 24 hours given diabetes and hypertension 4, 3
Administer sublingual or intravenous nitroglycerin for ongoing chest discomfort, and morphine can be used for pain relief if nitroglycerin is insufficient 1, 2

Plan for coronary angiography within 12-24 hours, as the European Society of Cardiology recommends early invasive strategy within 12-24 hours for high-risk patients 5, 6
High-risk features include recurrent ischemia, elevated troponin levels, ST-segment depression, and diabetes 1, 2

Do not withhold antithrombotic therapy due to recent surgery, as the mortality risk from untreated NSTEMI far exceeds bleeding risk in this scenario 1, 2
Do not attribute symptoms to GERD without ruling out ACS, as elevated troponin and ST-segment depressions confirm myocardial injury 1, 2

The European Society of Cardiology recommends aspirin 150-300 mg oral loading dose (or 75-250 mg IV) immediately, followed by 75-100 mg daily maintenance dose 7, 8, 9
The European Society of Cardiology suggests adding a P2Y12 inhibitor in addition to aspirin for 12 months unless contraindications exist 10, 9
Ticagrelor 180 mg loading dose, then 90 mg twice daily, is recommended for all moderate-to-high risk patients by the European Society of Cardiology 10, 9
The European Society of Cardiology recommends heparin (unfractionated or low-molecular-weight) should be initiated immediately 7, 8, 9
Beta-blockers are recommended as cornerstone therapy to reduce myocardial oxygen demand by decreasing heart rate and blood pressure by the European Society of Cardiology 7, 8

The European Society of Cardiology recommends coronary angiography should be performed within 24 hours (early invasive strategy) for patients with elevated troponin and dynamic ST changes 10, 9
Immediate invasive strategy (<2 hours) is reserved for very-high-risk features: hemodynamic instability, cardiogenic shock, refractory chest pain, life-threatening arrhythmias, or acute heart failure by the European Society of Cardiology 10, 9

The European Society of Cardiology advises against using fibrinolysis in NSTE-ACS—it is contraindicated and harmful 7, 8
The European Society of Cardiology recommends not delaying dual antiplatelet therapy—both aspirin and a P2Y12 inhibitor should be given immediately 10, 9

Elevated troponin identifies patients at high risk for progression to MI or death, according to the European Society of Cardiology 7, 8, 11
The European Society of Cardiology states that these high-risk patients derive the most benefit from intensive antiplatelet therapy and early invasive strategy 7, 8, 11

The European Society of Cardiology recommends adding a P2Y12 inhibitor with a loading dose immediately, such as ticagrelor 180 mg or clopidogrel 300-600 mg, to aspirin therapy for patients with NSTE-ACS 12
Continue aspirin 75-100 mg daily and ticagrelor 90 mg twice daily (or clopidogrel 75 mg daily) for 12 months 12
Start unfractionated heparin (UFH) or low molecular weight heparin (LMWH) immediately for anticoagulation 13
Initiate beta-blocker therapy to reduce myocardial oxygen demand by decreasing heart rate and blood pressure, with a target heart rate of 50-60 beats per minute 13
Administer sublingual or intravenous nitroglycerin for ongoing chest pain, with intravenous nitrates being more effective than sublingual for symptom relief and regression of ST depression 13
Titrate nitroglycerin dose upward until symptoms relieved or blood pressure normalized, unless side effects occur, and avoid giving nitrates if phosphodiesterase-5 inhibitor taken within 24 hours (sildenafil/vardenafil) or 48 hours (tadalafil) due to severe hypotension risk 13

This patient requires coronary angiography within 12-24 hours based on high-risk features: ST-segment depression in multiple leads, elevated troponin, and ongoing symptoms 12
The European Society of Cardiology recommends early invasive strategy within 24 hours for high-risk NSTE-ACS patients, although the specific guideline is not provided in the cited reference, the European Heart Journal is the journal of the European Society of Cardiology 12

Use established risk scores (GRACE, TIMI) for prognosis estimation, which can help identify patients at high risk for progression to MI or death who benefit most from intensive antiplatelet therapy and early invasive strategy 13
Morphine can be used for pain relief if nitroglycerin insufficient, though it may slow intestinal absorption of oral platelet inhibitors 13